Journal
JOURNAL OF NEUROLOGY
Volume 254, Issue 7, Pages 827-837Publisher
DR DIETRICH STEINKOPFF VERLAG
DOI: 10.1007/s00415-006-0486-3
Keywords
neutralising anti-bodies; interferon beta; multiple sclerosis; NAb; NAb-
Categories
Ask authors/readers for more resources
Interferon beta (IFN beta) therapy for multiple sclerosis (MS) is associated with a potential for the development of neutralising antibodies (NAbs) that negatively affect therapy. Several factors influence the development of NAbs, such as lack of complete sequence homology with the endogenous IFN beta sequence, frequency of administration, level of dose and formulation of IFN beta. Taken together, the evidence that NAb status reduces clinical efficacy in MS patients is strong. Standardised assays for NAbs are lacking, and titres vary over time. NAb testing is a critical component of care for MS patients because it provides information on one of the most important factors determining clinical responsiveness to IFN beta therapy. This expert panel report attempts to move the field towards resolution of the remaining issues and considers several aspects of NAbs, including their clinical relevance, factors influencing immunogenicity, assays to quantify NAbs and the definition of clinically relevant titres.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available